Top

Published in:

01-09-2009 | Preclinical Study

Vitreo-retinal traction and anastrozole use

Authors: Alvin Eisner, Emily J. Thielman, Julie Falardeau, John T. Vetto

Published in: Breast Cancer Research and Treatment | Issue 1/2009

Abstract

Purpose This study tested a prediction stemming from the hypothesis that anastrozole users experience heightened vitreo-retinal traction. This hypothesis was based on the knowledge that menopause increases the risk of intraocular tractional events such as posterior vitreous detachments (PVDs). Methods Retinal thickness was measured for 3 groups of amenorrheic women: (1) anastrozole users and (2) tamoxifen users undergoing adjuvant therapy for early-stage breast cancer, and (3) control subjects not using hormonal medication. Foveal shape indices were derived for subjects without PVDs. Results For anastrozole users, the distance to the temporal side of the fovea became less than the distance to the nasal side at a sufficient height above the foveal base. This effect did not exist for control subjects; the between-group difference was appreciable. Results concerning tamoxifen users were inconclusive. Conclusions The foveas of women using anastrozole appear to be subjected to more tractional force than are the foveas of women not using any hormonal medication.

Conte P, Frassoldati A (2007) Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective. Breast J 13:28–35. doi:10.1111/j.1524-4741.2006.00359.x PubMedCrossRef

Buzdar AU, Coombes RC, Goss PE et al (2008) Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112:700–709. doi:10.1002/cncr.23193 PubMedCrossRef

Partridge AH, LaFountain A, Mayer E et al (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562. doi:10.1200/JCO.2007.11.5451 PubMedCrossRef

Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62. doi:10.1016/S0140-6736(05)74803-0 PubMedCrossRef

Garreau JR, Delamelena T, Walts D et al (2006) Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg 192:496–498. doi:10.1016/j.amjsurg.2006.06.018 PubMedCrossRef

Barkhem T, Nilsson S, Gustafsson JA (2004) Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenomics 4:19–28. doi:10.2165/00129785-200404010-00003 PubMedCrossRef

Munaut C, Lambert V, Noel A et al (2001) Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol 85:877–882. doi:10.1136/bjo.85.7.877 PubMedCrossRef

Hayreh SS, Jonas JB (2004) Posterior vitreous detachment: clinical correlations. Ophthalmologica 218:333–343. doi:10.1159/000079476 PubMedCrossRef

The Eye Disease Case-Control Study Group (1994) Risk factors for idiopathic macular holes. Am J Ophthalmol 118:754–761

10.

Chuo JY, Lee TY, Hollands H et al (2006) Risk factors for posterior vitreous detachment: a case-control study. Am J Ophthalmol 142:931–937. doi:10.1016/j.ajo.2006.08.002 PubMedCrossRef

11.

Evans JR, Schwartz SD, McHugh JD et al (1998) Systemic risk factors for idiopathic macular holes: a case-control study. Eye 12(Pt 2):256–259PubMed

12.

Johnson MW (2005) Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc 103:537–567PubMed

13.

Smiddy WE, Flynn HW Jr (2004) Pathogenesis of macular holes and therapeutic implications. Am J Ophthalmol 137:525–537. doi:10.1016/j.ajo.2003.12.011 PubMedCrossRef

14.

van Velthoven ME, Faber DJ, Verbraak FD et al (2007) Recent developments in optical coherence tomography for imaging the retina. Prog Retin Eye Res 26:57–77. doi:10.1016/j.preteyeres.2006.10.002 PubMedCrossRef

15.

Eisner A, Falardeau J, Toomey MD et al (2008) Retinal hemorrhages in anastrozole users. Optom Vis Sci 85:301–308. doi:10.1097/OPX.0b013e31816bea3b PubMedCrossRef

16.

Eisner A, Toomey MD, Incognito LJ et al (2006) Contrasting blue-on-yellow with white-on-white visual fields: roles of visual adaptation for healthy peri- or postmenopausal women younger than 70 years of age. Invest Ophthalmol Vis Sci 47:5605–5614. doi:10.1167/iovs.05-1612 PubMedCrossRef

17.

Eisner A, Toomey MD (2008) The color appearance of stimuli detected via short-wavelength-sensitive cones: comparisons with visual adaptation and visual field data for peri- or post-menopausal women under 70 years of age. Vision Res. doi:10.1016/j.visres.2008.01.029 PubMed

18.

Eisner A, Toomey MD, Falardeau J et al (2007) Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. Breast Cancer Res Treat 106:161–170. doi:10.1007/s10549-006-9486-3 PubMedCrossRef

19.

Eisner A, Samples JR (2003) High blood pressure and visual sensitivity. J Opt Soc Am A Opt Image Sci Vis 20:1681–1693. doi:10.1364/JOSAA.20.001681 PubMedCrossRef

20.

Eisner A, Incognito LJ (2006) The color appearance of stimuli detected via short-wavelength-sensitive cones for breast cancer survivors using tamoxifen. Vision Res 46:1816–1822. doi:10.1016/j.visres.2005.11.003 PubMedCrossRef

21.

Eisner A, Austin DF, Samples JR (2004) Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol 88:125–130. doi:10.1136/bjo.88.1.125 PubMedCrossRef

22.

Gorin MB, Day R, Costantino JP et al (1998) Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 125:493–501. doi:10.1016/S0002-9394(99)80190-1 PubMedCrossRef

23.

Eisner A, O’Malley JP, Incognito LJ et al (2006) Small optic cup sizes among women using tamoxifen: assessment with scanning laser ophthalmoscopy. Curr Eye Res 31:367–379. doi:10.1080/02713680600602547 PubMedCrossRef

24.

Costa RA, Skaf M, Melo LA Jr et al (2006) Retinal assessment using optical coherence tomography. Prog Retin Eye Res 25:325–353. doi:10.1016/j.preteyeres.2006.03.001 PubMedCrossRef

25.

Uchino E, Uemura A, Ohba N (2001) Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. Arch Ophthalmol 119:1475–1479PubMed

26.

Ludbrook J (1998) Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 25:1032–1037. doi:10.1111/j.1440-1681.1998.tb02179.x PubMedCrossRef

27.

Chan A, Duker JS, Ko TH et al (2006) Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol 124:193–198. doi:10.1001/archopht.124.2.193 PubMedCrossRef

28.

Shields MB (1998) Optic nerve head and peripapillary retina. In: Textbook of glaucoma. Williams & Wilkins, Baltimore, pp 72–107

29.

Gonzalez Blanco F, Sanz Fernandez JC, Munoz Sanz MA (2008) Axial length, corneal radius, and age of myopia onset. Optom Vis Sci 85:89–96PubMedCrossRef

30.

Chui TY, Yap MK, Chan HH et al (2005) Retinal stretching limits peripheral visual acuity in myopia. Vision Res 45:593–605. doi:10.1016/j.visres.2004.09.016 PubMedCrossRef

31.

Enoch JM (1975) Marked accommodation, retinal stretch, monocular space perception and retinal receptor orientation. Am J Optom Physiol Opt 52:376–392PubMed

32.

Drasdo N, Fowler CW (1974) Non-linear projection of the retinal image in a wide-angle schematic eye. Br J Ophthalmol 58:709–714. doi:10.1136/bjo.58.8.709 PubMedCrossRef

33.

Cronin BG, Lekich CK, Bourke RD (2005) Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol 26:101–105. doi:10.1007/s10792-005-5424-3 PubMedCrossRef

34.

Zhang JJ, Jacob TJ, Valverde MA et al (1994) Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest 94:1690–1697. doi:10.1172/JCI117514 PubMedCrossRef

35.

Schaumberg DA, Sullivan DA, Buring JE et al (2003) Prevalence of dry eye syndrome among US women. Am J Ophthalmol 136:318–326. doi:10.1016/S0002-9394(03)00218-6 PubMedCrossRef

36.

Versura P, Campos EC (2005) Menopause and dry eye. A possible relationship. Gynecol Endocrinol 20:289–298. doi:10.1080/09513590400027257 PubMedCrossRef

Title: Vitreo-retinal traction and anastrozole use
Authors: Alvin Eisner
Emily J. Thielman
Julie Falardeau
John T. Vetto
Publication date: 01-09-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-0156-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Lobular involution: localized phenomenon or field effect?

Vitiligo in the affected breast during neo-adjuvant chemotherapy for breast cancer

Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer

Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo

Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu

TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro

Keynote webinar | Spotlight on antibody–drug conjugates in cancer